Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CervoMed (CRVO)
NASDAQ:CRVO
Holding CRVO?
Track your performance easily
CRVO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.80 - $26.38
Previous Close$2.23
Volume364.89K
Average Volume (3M)377.04K
Market Cap
$18.41M
Enterprise Value-$28.25M
Total Cash (Recent Filing)$46.66M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Apr 07, 2025EPS Estimate
-$0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding8,253,741
10 Day Avg. Volume1,744,150
30 Day Avg. Volume377,038
Standard Deviation0.33
R-Squared0.06
Alpha0.00375
Financial Highlights & Ratios
Price to Book (P/B)0.40
Price to Sales (P/S)1.83
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.92
Enterprise Value/Gross Profit-3.95
Enterprise Value/Ebitda4.40
Forecast
1Y Price Target
$8.00Price Target Upside258.74% Upside
Rating ConsensusHold
Number of Analyst Covering8
CervoMed News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNeflamapimod showed a favorable safety and tolerability profile in the Phase 2b trial, consistent with prior studies, with no new safety signals identified.
Financial PositionCervoMed ended with $46.7M in cash and cash equivalents, providing the company with strategic options regardless of the ultimate outcome of neflamapimod.
Market PotentialCervoMed's lead program targets a previously unexplored niche disease area, offering a unique value proposition with potential sales exceeding $1B in the U.S. market.
Bears Say
Clinical Trial ResultsCervoMed's Phase 2b trial in dementia with Lewy bodies did not meet primary and secondary endpoints.
Stock DowngradeCRVO shares have been downgraded to Underweight as better opportunities are seen elsewhere.
Uncertainty In Drug DevelopmentOutstanding uncertainty for neflamapimod development in DLB and limited catalysts beyond the OLE data lead to a downgrade of CRVO shares to Underweight.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRVO FAQ
What was CervoMed’s price range in the past 12 months?
CervoMed lowest stock price was $1.80 and its highest was $26.38 in the past 12 months.
What is CervoMed’s market cap?
Currently, no data Available
When is CervoMed’s upcoming earnings report date?
CervoMed’s upcoming earnings report date is Apr 07, 2025 which is in 107 days.
How were CervoMed’s earnings last quarter?
CervoMed released its earnings results on Nov 12, 2024. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.412 by -$0.138.
Is CervoMed overvalued?
According to Wall Street analysts CervoMed’s price is currently Undervalued.
Does CervoMed pay dividends?
CervoMed does not currently pay dividends.
What is CervoMed’s EPS estimate?
CervoMed’s EPS estimate is -$0.62.
How many shares outstanding does CervoMed have?
CervoMed has 8,253,741 shares outstanding.
What happened to CervoMed’s price movement after its last earnings report?
CervoMed reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.412. Following the earnings report the stock price went down -2.554%.
Which hedge fund is a major shareholder of CervoMed?
Among the largest hedge funds holding CervoMed’s share is RA Capital Management. It holds CervoMed’s shares valued at 12M.
---
CervoMed Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$8.00 (258.74% Upside)
$8.00 (258.74% Upside)
Crowd Wisdom
Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.63%
12-Months-Change
Fundamentals
Return on Equity
-43.28%
Trailing 12-Months
Asset Growth
306.08%
Trailing 12-Months
Company Description
CervoMed
Diffusion Pharmaceuticals, Inc. is a clinical stage company which engages lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate, for use in those life threatening conditions in which cellular oxygen deprivation is the basis for significant unmet medical needs. The company was founded by David G. Kalergis and John L. Gainer in 2001 and is headquartered in Charlottesville, VA.
---
CRVO Stock 12 Month Forecast
Average Price Target
$8.00
▲(258.74% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Aldeyra Therapeutics
―
EyePoint Pharmaceuticals
―
Kala Pharmaceuticals
―
Best Analysts Covering CRVO
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-74.78%
reiterated a buy rating 12 days ago
Copying Sumant Kulkarni's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -74.78% per trade.
---